BIOMAT Database Logo BIOMAT Database Logo

Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents. 1991

D A Clark, and S W Goldstein, and R A Volkmann, and J F Eggler, and G F Holland, and B Hulin, and R W Stevenson, and D K Kreutter, and E M Gibbs, and M N Krupp
Pfizer, Inc., Groton, Connecticut 06340.

A series of dihydrobenzofuran and dihydrobenzopyran thiazolidine-2,4-diones (compounds 3-26) was synthesized from the corresponding aryl aldehydes 1 in two steps. These compounds represent conformationally restricted analogues of the novel hypoglycemic ciglitazone. The series was evaluated by hypoglycemic effects in vitro by measuring stimulation of 2-deoxyglucose uptake in L6 myocytes and stimulation of expression of the glucose transporter protein in 3T3-L1 adipocytes. In vivo hypoglycemic effects were evaluated in the genetically obese ob/ob mouse, and structure-activity relationships are discussed. On the basis of this in vivo potency, we have selected the 2(R)-benzylbenzopyran derivative to be further studied in a clinical setting.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007202 Indicators and Reagents Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant & Hackh's Chemical Dictionary, 5th ed, p301, p499) Indicator,Reagent,Reagents,Indicators,Reagents and Indicators
D008820 Mice, Obese Mutant mice exhibiting a marked obesity coupled with overeating, hyperglycemia, hyperinsulinemia, marked insulin resistance, and infertility when in a homozygous state. They may be inbred or hybrid. Hyperglycemic Mice,Obese Mice,Mouse, Hyperglycemic,Mouse, Obese,Hyperglycemic Mouse,Mice, Hyperglycemic,Obese Mouse
D009004 Monosaccharide Transport Proteins A large group of membrane transport proteins that shuttle MONOSACCHARIDES across CELL MEMBRANES. Hexose Transport Proteins,Band 4.5 Preactin,Erythrocyte Band 4.5 Protein,Glucose Transport-Inducing Protein,Hexose Transporter,4.5 Preactin, Band,Glucose Transport Inducing Protein,Preactin, Band 4.5,Proteins, Monosaccharide Transport,Transport Proteins, Hexose,Transport Proteins, Monosaccharide,Transport-Inducing Protein, Glucose
D009132 Muscles Contractile tissue that produces movement in animals. Muscle Tissue,Muscle,Muscle Tissues,Tissue, Muscle,Tissues, Muscle
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003847 Deoxyglucose 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity. 2-Deoxy-D-glucose,2-Deoxyglucose,2-Desoxy-D-glucose,2 Deoxy D glucose,2 Deoxyglucose,2 Desoxy D glucose
D006943 Hyperglycemia Abnormally high BLOOD GLUCOSE level. Postprandial Hyperglycemia,Hyperglycemia, Postprandial,Hyperglycemias,Hyperglycemias, Postprandial,Postprandial Hyperglycemias
D000273 Adipose Tissue Specialized connective tissue composed of fat cells (ADIPOCYTES). It is the site of stored FATS, usually in the form of TRIGLYCERIDES. In mammals, there are two types of adipose tissue, the WHITE FAT and the BROWN FAT. Their relative distributions vary in different species with most adipose tissue being white. Fatty Tissue,Body Fat,Fat Pad,Fat Pads,Pad, Fat,Pads, Fat,Tissue, Adipose,Tissue, Fatty
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

D A Clark, and S W Goldstein, and R A Volkmann, and J F Eggler, and G F Holland, and B Hulin, and R W Stevenson, and D K Kreutter, and E M Gibbs, and M N Krupp
(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents.
February 1999, Bioorganic & medicinal chemistry letters,
D A Clark, and S W Goldstein, and R A Volkmann, and J F Eggler, and G F Holland, and B Hulin, and R W Stevenson, and D K Kreutter, and E M Gibbs, and M N Krupp
Benzyloxazolidine-2,4-diones as potent hypoglycemic agents.
May 1991, Journal of medicinal chemistry,
D A Clark, and S W Goldstein, and R A Volkmann, and J F Eggler, and G F Holland, and B Hulin, and R W Stevenson, and D K Kreutter, and E M Gibbs, and M N Krupp
[Quantitative structure-hypoglycemic activity relationships of some thiazolidine and imidazolidine-2,4-diones].
January 1993, Annales pharmaceutiques francaises,
D A Clark, and S W Goldstein, and R A Volkmann, and J F Eggler, and G F Holland, and B Hulin, and R W Stevenson, and D K Kreutter, and E M Gibbs, and M N Krupp
Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones.
August 2000, Journal of medicinal chemistry,
D A Clark, and S W Goldstein, and R A Volkmann, and J F Eggler, and G F Holland, and B Hulin, and R W Stevenson, and D K Kreutter, and E M Gibbs, and M N Krupp
Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: Potential anticancer agents.
November 2014, European journal of medicinal chemistry,
D A Clark, and S W Goldstein, and R A Volkmann, and J F Eggler, and G F Holland, and B Hulin, and R W Stevenson, and D K Kreutter, and E M Gibbs, and M N Krupp
5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.
May 2003, Bioorganic & medicinal chemistry letters,
D A Clark, and S W Goldstein, and R A Volkmann, and J F Eggler, and G F Holland, and B Hulin, and R W Stevenson, and D K Kreutter, and E M Gibbs, and M N Krupp
Novel 5-(3-aryl-2-propynyl)-5-(arylsulfonyl)thiazolidine-2,4-diones as antihyperglycemic agents.
March 1998, Journal of medicinal chemistry,
D A Clark, and S W Goldstein, and R A Volkmann, and J F Eggler, and G F Holland, and B Hulin, and R W Stevenson, and D K Kreutter, and E M Gibbs, and M N Krupp
5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents.
August 2003, Bioorganic & medicinal chemistry letters,
D A Clark, and S W Goldstein, and R A Volkmann, and J F Eggler, and G F Holland, and B Hulin, and R W Stevenson, and D K Kreutter, and E M Gibbs, and M N Krupp
Thiazolidine-2,4-diones: progress towards multifarious applications.
April 2013, Bioorganic & medicinal chemistry,
D A Clark, and S W Goldstein, and R A Volkmann, and J F Eggler, and G F Holland, and B Hulin, and R W Stevenson, and D K Kreutter, and E M Gibbs, and M N Krupp
Synthesis and Hypoglycemic and Anti-inflammatory Activity Screening of Novel Substituted 5-[Morpholino(Phenyl)Methyl]-Thiazolidine-2,4-Diones and Their Molecular Docking Studies.
December 2019, Turkish journal of pharmaceutical sciences,
Copied contents to your clipboard!